Efficacy of Motivational Interviewing in Treating Co-occurring Psychosis and Substance Use Disorder: A Systematic Review and Meta-Analysis

References (75)

1. Sara GE, Burgess PM, Malhi GS, et al. Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample. Aust N Z J Psychiatry. 2014;48(11):1036–1047. PubMed CrossRef
2. Brunette MF, Mueser KT, Babbin S, et al. Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophr Res. 2018;194:4–12. PubMed CrossRef
3. Hunt GE, Large MM, Cleary M, et al. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234–258. PubMed CrossRef
4. Barrowclough C, Haddock G, Fitzsimmons M, et al. Treatment development for psychosis and co-occurring substance misuse: a descriptive review. J Ment Health. 2006;15(6):619–632. CrossRef
5. Grech A, Van Os J, Jones PB, et al. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry. 2005;20(4):349–353. PubMed CrossRef
6. van Os J, Bak M, Hanssen M, et al. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156(4):319–327. PubMed CrossRef
7. Dom G, Moggi F. Co-occurring Addictive and Psychiatric Disorders. Springer Berlin Heidelberg; 2015.
8. Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(suppl):1–56. PubMed
9. National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults: Prevention and Management (NICE Clinical Guideline No. 178). National Institute for Health and Care Excellence website. https://www.nice.org.uk/guidance/cg178. 2014.
10. Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev. 2005;29(6):1021–1034. PubMed CrossRef
11. Fiorentini A, Volonteri LS, Dragogna F, et al. Substance-induced psychoses: a critical review of the literature. Curr Drug Abuse Rev. 2011;4(4):228–240. PubMed CrossRef
12. Bramness JG, Gundersen OH, Guterstam J, et al. Amphetamine-induced psychosis: a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry. 2012;12(1):221. PubMed CrossRef
13. Martino S, Carroll K, Kostas D, et al. Dual Diagnosis Motivational Interviewing: a modification of Motivational Interviewing for substance-abusing patients with psychotic disorders. J Subst Abuse Treat. 2002;23(4):297–308. PubMed CrossRef
14. National Institute for Health and Care Excellence. Coexisting Severe Mental Illness (Psychosis) and Substance Misuse: Assessment and Management in Healthcare Settings (NICE Clinical Guideline No. 120). National Institute for Health and Care Excellence website. https://www.nice.org.uk/guidance/cg120. 2011.
15. Miller WR. Motivational interviewing with problem drinking. Behav Cogn Psychother. 1983;11(2):147–172. CrossRef
16. Miller WR, Rollnick S. Motivational Interviewing: Helping People Change. 3rd ed. Guilford Press; 2013.
17. Arkowitz H, Westra HA, Miller WR, et al. Motivational Interviewing in the Treatment of Psychological Problems. 2nd ed. Guilford Press; 2015.
18. Lundahl BW, Kunz C, Brownell C, et al. A meta-analysis of motivational interviewing: twenty-five years of empirical studies. Res Soc Work Pract. 2010;20(2):137–160. CrossRef
19. Burke BL, Arkowitz H, Menchola M. The efficacy of motivational interviewing: a meta-analysis of controlled clinical trials. J Consult Clin Psychol. 2003;71(5):843–861. PubMed CrossRef
20. Hettema J, Steele J, Miller WR. Motivational interviewing. Annu Rev Clin Psychol. 2005;1(1):91–111. PubMed CrossRef
21. Rubak S, Sandbaek A, Lauritzen T, et al. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005;55(513):305–312. PubMed
22. Vasilaki EI, Hosier SG, Cox WM. The efficacy of motivational interviewing as a brief intervention for excessive drinking: a meta-analytic review. Alcohol Alcohol. 2006;41(3):328–335. PubMed CrossRef
23. Amrhein PC, Miller WR, Yahne CE, et al. Client commitment language during motivational interviewing predicts drug use outcomes. J Consult Clin Psychol. 2003;71(5):862–878. PubMed CrossRef
24. Miller WR, Rose GS. Toward a theory of motivational interviewing. Am Psychol. 2009;64(6):527–537. PubMed CrossRef
25. Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change. 2nd ed. Guilford Press; 2002.
26. Graeber DA, Moyers TB, Griffith G, et al. A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. Community Ment Health J. 2003;39(3):189–202. PubMed CrossRef
27. Kemp R, Harris A, Vurel E, et al. Stop Using Stuff: trial of a drug and alcohol intervention for young people with comorbid mental illness and drug and alcohol problems. Australas Psychiatry. 2007;15(6):490–493. PubMed CrossRef
28. Barrowclough C, Haddock G, Tarrier N, et al. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry. 2001;158(10):1706–1713. PubMed CrossRef
29. Cleary M, Hunt GE, Matheson S, et al. Psychosocial treatment programs for people with both severe mental illness and substance misuse. Schizophr Bull. 2008;34(2):226–228. PubMed CrossRef
30. De Witte NA, Crunelle CL, Sabbe B, et al. Treatment for outpatients with comorbid schizophrenia and substance use disorders: a review. Eur Addict Res. 2014;20(3):105–114. PubMed CrossRef
31. Hjorthøj C, Fohlmann A, Nordentoft M. Treatment of cannabis use disorders in people with schizophrenia spectrum disorders: a systematic review. Addict Behav. 2009;34(6-7):520–525. PubMed CrossRef
32. Lubman DI, King JA, Castle DJ. Treating comorbid substance use disorders in schizophrenia. Int Rev Psychiatry. 2010;22(2):191–201. PubMed CrossRef
33. Tsuang J, Fong TW. Treatment of patients with schizophrenia and substance abuse disorders. Curr Pharm Des. 2004;10(18):2249–2261. PubMed CrossRef
34. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34. PubMed CrossRef
35. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. PubMed CrossRef
36. Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behavior. Guilford Press; 1991.
37. Borenstein M, Hedges LV, Higgins JP, et al. Comprehensive Meta-Analysis Version 2.0. Biostat Inc; 2005.
38. Hedges LV. Distribution theory for Glass’s estimator of effect size and related estimators. J Educ Behav Stat. 1981;6(2):107–128. CrossRef
39. Cohen J. Statistical Power Analyses for the Behavioral Sciences. 2nd ed. Routledge Academic; 1988.
40. Borenstein MHL, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. John Wiley & Sons; 2009.
41. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13. PubMed CrossRef
42. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. PubMed CrossRef
43. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10(3):799–812. CrossRef
44. Jauhar S, McKenna PJ, Radua J, et al. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry. 2014;204(1):20–29. PubMed CrossRef
45. Dawe S, Mattick RP. Review of Diagnostic Screening Instruments for Alcohol and Other Drug Use and Other Psychiatric Disorders. Australian Government Publishing Service; 1997.
46. Skinner HA. The Drug Abuse Screening Test. Addict Behav. 1982;7(4):363–371. PubMed CrossRef
47. McLellan AT, Luborsky L, Woody GE, et al. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 1980;168(1):26–33. PubMed CrossRef
48. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. PubMed CrossRef
49. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. PubMed CrossRef
50. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–463. PubMed CrossRef
51. Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.2. Cochrane website. 2021. http://www.training.cochrane.org/handbook
52. Tantirangsee N, Assanangkornchai S, Marsden J. Effects of a brief intervention for substance use on tobacco smoking and family relationship functioning in schizophrenia and related psychoses: a randomised controlled trial. J Subst Abuse Treat. 2015;51:30–37. PubMed CrossRef
53. Kavanagh DJ, Young R, White A, et al. A brief motivational intervention for substance misuse in recent-onset psychosis. Drug Alcohol Rev. 2004;23(2):151–155. PubMed CrossRef
54. Bonsack C, Gibellini Manetti S, Favrod J, et al. Motivational intervention to reduce cannabis use in young people with psychosis: a randomized controlled trial. Psychother Psychosom. 2011;80(5):287–297. PubMed CrossRef
55. Brunette MF, Ferron JC, McGurk SR, et al. Brief, web-based interventions to motivate smokers with schizophrenia: randomized controlled trial. JMIR Ment Health. 2020;7(2):e16524. PubMed CrossRef
56. Haddock G, Barrowclough C, Tarrier N, et al. Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomised controlled trial. Br J Psychiatry. 2003;183(5):418–426. PubMed CrossRef
57. James W, Preston NJ, Koh G, et al. A group intervention which assists patients with dual diagnosis reduce their drug use: a randomized controlled trial. Psychol Med. 2004;34(6):983–990. PubMed CrossRef
58. Baker A, Bucci S, Lewin TJ, et al. Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: randomised controlled trial. Br J Psychiatry. 2006;188(5):439–448. PubMed CrossRef
59. Johnson S, Thornicroft G, Afuwape S, et al. Effects of training community staff in interventions for substance misuse in dual diagnosis patients with psychosis (COMO study): cluster randomised trial. Br J Psychiatry. 2007;191(5):451–452. PubMed CrossRef
60. Craig TKJ, Johnson S, McCrone P, et al. Integrated care for co-occurring disorders: psychiatric symptoms, social functioning, and service costs at 18 months. Psychiatr Serv. 2008;59(3):276–282. PubMed CrossRef
61. Barrowclough C, Haddock G, Wykes T, et al. Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. BMJ. 2010;24(341):c6325. PubMed CrossRef
62. Williams JM, Steinberg ML, Zimmermann MH, et al. Comparison of two intensities of tobacco dependence counseling in schizophrenia and schizoaffective disorder. J Subst Abuse Treat. 2010;38(4):384–393. PubMed CrossRef
63. Morrens M, Dewilde B, Sabbe B, et al. Treatment outcomes of an integrated residential programme for patients with schizophrenia and substance use disorder. Eur Addict Res. 2011;17(3):154–163. PubMed CrossRef
64. Hjorthøj CR, Fohlmann A, Larsen AM, et al. Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial. Psychol Med. 2013;43(7):1499–1510. PubMed CrossRef
65. Madigan K, Brennan D, Lawlor E, et al. A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness. Schizophr Res. 2013;143(1):138–142. PubMed CrossRef
66. Barrowclough C, Marshall M, Gregg L, et al. A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis: a randomized controlled trial. Psychol Med. 2014;44(13):2749–2761. PubMed CrossRef
67. Gouzoulis-Mayfrank E, König S, Koebke S, et al. Trans-sector integrated treatment in psychosis and addiction: a randomized controlled study of a motivational, cognitive behavioral therapy program under standard hospital treatment conditions. Dtsch Arztebl Int. 2015;112(41):683–691. PubMed
68. Sobell LC, Sobell MB. Timeline follow-back. In: Litten RZ, Allen JP, eds. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Humana Press; 1992:41–72.
69. Darke S, Ward J, Hall W, et al. The Opiate Treatment Index (OTI) Manual. Technical Report Number 11. National Drug and Alcohol Research Centre; 1991.
70. Andreasen NC. The Scale for Assessment of Positive Symptoms (SAPS). University of Iowa; 1984.
71. Andreasen NC. The Scale for Assessment of Negative Symptoms (SANS). University of Iowa; 1983.
72. Dumaine ML. Meta-analysis of interventions with co-occurring disorders of severe mental illness and substance abuse: implications for social work practice. Res Soc Work Pract. 2003;13(2):142–165. CrossRef
73. Riper H, Andersson G, Hunter SB, et al. Treatment of comorbid alcohol use disorders and depression with cognitive-behavioural therapy and motivational interviewing: a meta-analysis. Addiction. 2014;109(3):394–406. PubMed CrossRef
74. Baker AL, Hides L, Lubman DI. Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. J Clin Psychiatry. 2010;71(3):247–254. PubMed CrossRef
75. Carney T, Myers B. Effectiveness of early interventions for substance-using adolescents: findings from a systematic review and meta-analysis. Subst Abuse Treat Prev Policy. 2012;7(1):25. PubMed CrossRef